Dr. Salloway and colleagues reply

New England Journal of Medicine

Volumn 370, Issue 15, 2014, Pages 1460-

  Salloway, Stephen ^a   Sperling, Reisa ^b   Brashear, H Robert ^c  

^a BROWN UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PROTEIN; TAU PROTEIN; AMYLOID BETA PROTEIN; MONOCLONAL ANTIBODY;

ALZHEIMER DISEASE; CARDIOVASCULAR RISK; DISEASE COURSE; HUMAN; LETTER; NERVE DEGENERATION; PRIORITY JOURNAL; PROTEIN MODIFICATION; DRUG ANTAGONISM; FEMALE; MALE; NOTE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MALE;

EID: 84898752869     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1402193     Document Type: Letter

References (7)

1. S Salloway R Sperling NC Fox Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease N Engl J Med 370 2014 322 333
2. RS Doody RG Thomas M Farlow Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease N Engl J Med 370 2014 311 321
3. HW Querfurth FM LaFerla Alzheimer's disease N Engl J Med 362 2010 329 344
4. E Karran J Hardy Antiamyloid therapy for Alzheimer's disease — are we on the right road? N Engl J Med 370 2014 377 378
5. JC de la Torre Vascular risk factors: a ticking time bomb to Alzheimer's disease Am J Alzheimers Dis Other Demen 28 2013 551 559
6. RS Doody RG Thomas M Farlow Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease N Engl J Med 370 2014 311 321
7. LE Hebert LA Beckett PA Scherr DA Evans Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050 Alzheimer Dis Assoc Disord 15 2001 169 173